Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
222 hedge funds and large institutions have $4.19B invested in Prometheus Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 95 funds opening new positions, 72 increasing their positions, 47 reducing their positions, and 16 closing their positions.
494% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 16
116% more capital invested
Capital invested by funds: $1.94B → $4.19B (+$2.25B)
70% more funds holding in top 10
Funds holding in top 10: 10 → 17 (+7)
54% more funds holding
Funds holding: 144 → 222 (+78)
53% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 47
4% less call options, than puts
Call options by funds: $220M | Put options by funds: $230M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$43.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$43.7M |
| 3 |
D.E. Shaw & Co
New York
|
+$36.6M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$29.7M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$106M |
| 2 |
CA
CHI Advisors
New York
|
-$44M |
| 3 |
PA
Perceptive Advisors
New York
|
-$16.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.5M |
| 5 |
State Street
Boston,
Massachusetts
|
-$15.4M |
RXDX Hedge Fund Activity: Q4 2022 in Review
222 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q4 2022, worth a combined $4.19B — up 116% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new RXDX positions and 16 closed out — a net gain of 79 holders — while 72 added to existing stakes and 47 trimmed.
The largest buyer was BlackRock, adding an estimated $43.7M. The largest seller was Eventide Asset Management, cutting an estimated $106M.
- 222 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q4 2022, up from 144 in Q3 2022.
- Funds reported $4.19B of Prometheus Biosciences, Inc. Common Stock stock for Q4 2022, up 116% quarter-over-quarter.
- 95 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q4 2022 and 16 closed out, a net change of +79 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q4 2022 was BlackRock, an estimated $43.7M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q4 2022 was Eventide Asset Management, an estimated $106M sold.
Based on aggregated 13F filings for Q4 2022.